Pfizer Pre-Tax Profit Margin 2012-2026 | PFE
Current and historical pre-tax profit margin for Pfizer (PFE) from 2012 to 2026. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Pfizer pre-tax profit margin for the three months ending March 31, 2026 was .
| Pfizer Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2026-03-31 | $63.32B | $7.91B | 12.49% |
| 2025-12-31 | $62.58B | $7.52B | 12.02% |
| 2025-09-30 | $62.79B | $9.15B | 14.58% |
| 2025-06-30 | $63.83B | $10.53B | 16.50% |
| 2025-03-31 | $62.46B | $7.39B | 11.83% |
| 2024-12-31 | $63.63B | $8.02B | 12.61% |
| 2024-09-30 | $60.43B | $3.90B | 6.46% |
| 2024-06-30 | $56.22B | $-4.16B | -7.40% |
| 2024-03-31 | $55.95B | $-1.79B | -3.20% |
| 2023-12-31 | $59.55B | $1.06B | 1.78% |
| 2023-09-30 | $70.12B | $10.42B | 14.86% |
| 2023-06-30 | $79.27B | $22.77B | 28.73% |
| 2023-03-31 | $94.00B | $31.95B | 33.99% |
| 2022-12-31 | $101.18B | $34.73B | 34.33% |
| 2022-09-30 | $99.88B | $33.33B | 33.37% |
| 2022-06-30 | $101.28B | $32.17B | 31.76% |
| 2022-03-31 | $92.43B | $27.67B | 29.93% |
| 2021-12-31 | $81.29B | $24.31B | 29.91% |
| 2021-09-30 | $68.88B | $21.08B | 30.61% |
| 2021-06-30 | $55.12B | $13.81B | 25.05% |
| 2021-03-31 | $46.08B | $9.89B | 21.45% |
| 2020-12-31 | $41.65B | $7.04B | 16.89% |
| 2020-09-30 | $32.07B | $-1.43B | -4.47% |
| 2020-06-30 | $34.47B | $8.73B | 25.31% |
| 2020-03-31 | $37.87B | $9.84B | 25.98% |
| 2019-12-31 | $40.91B | $11.32B | 27.68% |
| 2019-09-30 | $40.22B | $9.95B | 24.75% |
| 2019-06-30 | $40.84B | $3.40B | 8.34% |
| 2019-03-31 | $41.04B | $3.79B | 9.24% |
| 2018-12-31 | $40.83B | $3.59B | 8.80% |
| 2018-09-30 | $53.37B | $13.79B | 25.83% |
| 2018-06-30 | $53.24B | $13.19B | 24.78% |
| 2018-03-31 | $52.67B | $12.48B | 23.70% |
| 2017-12-31 | $52.55B | $12.31B | 23.42% |
| 2017-09-30 | $52.47B | $12.13B | 23.11% |
| 2017-06-30 | $52.35B | $10.15B | 19.38% |
| 2017-03-31 | $52.60B | $8.74B | 16.62% |
| 2016-12-31 | $52.82B | $8.35B | 15.81% |
| 2016-09-30 | $53.24B | $7.22B | 13.56% |
| 2016-06-30 | $52.29B | $8.32B | 15.90% |
| 2016-03-31 | $50.99B | $9.44B | 18.52% |
| 2015-12-31 | $48.85B | $8.97B | 18.35% |
| 2015-09-30 | $47.92B | $11.12B | 23.21% |
| 2015-06-30 | $48.20B | $12.01B | 24.92% |
| 2015-03-31 | $49.12B | $12.48B | 25.40% |
| 2014-12-31 | $49.61B | $12.24B | 24.67% |
| 2014-09-30 | $50.05B | $13.50B | 26.97% |
| 2014-06-30 | $50.33B | $13.48B | 26.79% |
| 2014-03-31 | $50.53B | $14.84B | 29.37% |
| 2013-12-31 | $51.58B | $15.72B | 30.47% |
| 2013-09-30 | $50.88B | $14.48B | 28.45% |
| 2013-06-30 | $51.19B | $13.71B | 26.78% |
| 2013-03-31 | $52.18B | $12.53B | 24.02% |
| 2012-12-31 | $54.66B | $11.24B | 20.57% |
| 2012-09-30 | $53.25B | $10.65B | 19.99% |
| 2012-06-30 | $56.90B | $11.38B | 20.00% |
| 2012-03-31 | $59.42B | $10.80B | 18.17% |
| 2011-12-31 | $61.04B | $11.48B | 18.81% |
| 2011-09-30 | $65.06B | $11.24B | 17.28% |
| 2011-06-30 | $64.44B | $9.11B | 14.14% |
| 2011-03-31 | $65.09B | $9.44B | 14.50% |
| 2010-12-31 | $65.17B | $9.47B | 14.53% |
| 2010-09-30 | $65.50B | $8.34B | 12.73% |
| 2010-06-30 | $61.13B | $10.90B | 17.83% |
| 2010-03-31 | $54.98B | $10.02B | 18.23% |
| 2009-12-31 | $49.27B | $10.67B | 21.66% |
| 2009-09-30 | $45.82B | $11.45B | 24.99% |
| 2009-06-30 | $46.17B | $10.20B | 22.09% |
| 2009-03-31 | $47.32B | $9.94B | 21.01% |
| 2008-12-31 | $48.30B | $9.69B | 20.07% |
| 2008-09-30 | $48.82B | $12.04B | 24.66% |
| 2008-06-30 | $48.84B | $9.95B | 20.38% |
| 2008-03-31 | $47.79B | $8.78B | 18.38% |
| 2007-12-31 | $48.42B | $9.28B | 19.16% |
| 2007-09-30 | $48.15B | $8.02B | 16.66% |
| 2007-06-30 | $48.44B | $11.35B | 23.42% |
| 2007-03-31 | $49.10B | $12.81B | 26.09% |
| 2006-12-31 | $48.37B | $13.03B | 26.93% |
| 2006-09-30 | $47.37B | $14.28B | 30.15% |
| 2006-06-30 | $46.35B | $12.33B | 26.60% |
| 2006-03-31 | $46.06B | $12.16B | 26.40% |
| 2005-12-31 | $47.41B | $10.80B | 22.78% |
| 2005-09-30 | $47.20B | $10.73B | 22.73% |
| 2005-06-30 | $48.77B | $12.67B | 25.97% |
| 2005-03-31 | $49.59B | $13.18B | 26.58% |
| 2004-12-31 | $48.99B | $13.40B | 27.36% |
| 2004-09-30 | $51.57B | $11.46B | 22.21% |
| 2004-06-30 | $51.09B | $9.99B | 19.56% |
| 2004-03-31 | $48.72B | $3.16B | 6.48% |
| 2003-12-31 | $44.74B | $3.25B | 7.26% |
| 2003-09-30 | $40.01B | $5.73B | 14.33% |
| 2003-06-30 | $35.66B | $6.14B | 17.23% |
| 2003-03-31 | $33.05B | $11.92B | 36.07% |
| 2002-12-31 | $32.29B | $11.77B | 36.43% |
| 2002-09-30 | $29.03B | $10.57B | 36.41% |
| 2002-06-30 | $28.86B | $10.43B | 36.12% |
| 2002-03-31 | $29.19B | $10.44B | 35.78% |
| 2001-12-31 | $29.02B | $9.98B | 34.40% |
| 2001-09-30 | $31.14B | $8.46B | 27.18% |
| 2001-06-30 | $30.47B | $7.49B | 24.59% |
| 2001-03-31 | $29.84B | $6.77B | 22.68% |
| 2000-12-31 | $29.41B | $4.58B | 15.56% |
| 2000-09-30 | $25.81B | $5.17B | 20.01% |
| 2000-06-30 | $21.99B | $4.35B | 19.78% |
| 2000-03-31 | $18.78B | $3.71B | 19.75% |
| 1999-12-31 | $15.54B | $4.45B | 28.62% |
| 1999-09-30 | $14.90B | $3.17B | 21.30% |
| 1999-06-30 | $14.90B | $2.91B | 19.52% |
| 1999-03-31 | $14.24B | $2.78B | 19.53% |
| 1998-12-31 | $13.35B | $2.59B | 19.44% |
| 1998-09-30 | $12.39B | $3.34B | 26.98% |
| 1998-06-30 | $11.71B | $3.45B | 29.48% |
| 1998-03-31 | $11.09B | $3.19B | 28.75% |
| 1997-12-31 | $10.74B | $3.09B | 28.76% |
| 1997-09-30 | $10.99B | $3.04B | 27.65% |
| 1997-06-30 | $11.14B | $2.98B | 26.71% |
| 1997-03-31 | $11.31B | $2.91B | 25.76% |
| 1996-12-31 | $11.31B | $2.80B | 24.80% |
| 1996-09-30 | $10.89B | $2.64B | 24.25% |
| 1996-06-30 | $10.63B | $2.52B | 23.71% |
| 1996-03-31 | $10.37B | $2.42B | 23.36% |
| 1995-12-31 | $10.02B | $2.30B | 22.95% |
| 1995-09-30 | $9.58B | $2.21B | 23.11% |
| 1995-06-30 | $9.11B | $2.07B | 22.70% |
| 1995-03-31 | $8.64B | $1.96B | 22.73% |
| 1994-12-31 | $8.28B | $1.86B | 22.49% |
| 1994-09-30 | $7.97B | $1.78B | 22.27% |
| 1994-06-30 | $7.77B | $0.96B | 12.41% |
| 1994-03-31 | $7.59B | $0.94B | 12.35% |
| 1993-12-31 | $7.48B | $0.85B | 11.39% |
| 1993-09-30 | $7.44B | $0.87B | 11.63% |
| 1993-06-30 | $7.39B | $1.60B | 21.58% |
| 1993-03-31 | $7.34B | $1.58B | 21.52% |
| 1992-12-31 | $7.23B | $1.53B | 21.22% |
| 1992-09-30 | $7.13B | $1.10B | 15.35% |
| 1992-06-30 | $7.08B | $1.06B | 14.93% |
| 1992-03-31 | $7.02B | $0.98B | 13.90% |
| 1991-12-31 | $6.95B | $0.94B | 13.58% |
| 1991-09-30 | $6.89B | $1.19B | 17.30% |
| 1991-06-30 | $6.76B | $1.16B | 17.20% |
| 1991-03-31 | $6.62B | $1.13B | 16.99% |
| 1990-12-31 | $6.41B | $1.10B | 17.23% |
| 1990-09-30 | $6.12B | $0.98B | 16.08% |
| 1990-06-30 | $5.91B | $0.95B | 16.04% |
| 1990-03-31 | $5.72B | $0.93B | 16.25% |
| 1989-12-31 | $5.67B | $0.92B | 16.17% |
| 1989-09-30 | $5.55B | $1.02B | 18.46% |
| 1989-06-30 | $5.49B | $1.03B | 18.78% |
| 1989-03-31 | $5.52B | $1.13B | 20.51% |
| 1988-12-31 | $5.39B | $1.10B | 20.50% |
| 1988-09-30 | $5.29B | $1.09B | 20.54% |
| 1988-06-30 | $5.21B | $1.06B | 20.34% |
| 1988-03-31 | $5.10B | $1.03B | 20.16% |
| 1987-12-31 | $4.92B | $1.01B | 20.57% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |